Profiling ocular surface responses to preserved and non‐preserved topical glaucoma medications: a two‐year randomised evaluation study by Mohammed, Imran et al.
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/ceo.13814 
 
Original Article – Laboratory Science 
 
Profiling ocular surface responses to preserved and non-
preserved topical glaucoma medications: a two-year 
randomised evaluation study 
 
Imran Mohammed PhD, Bina Kulkarni PhD, Lana A. Faraj PhD, Ali Abbas MBBCh, 
Harminder S. Dua PhD* and Anthony J. King MD* 
 
Academic Ophthalmology, Division of Clinical Neuroscience, University of 
Nottingham, Nottingham NG7 2UH, United Kingdom 
 
* Equally contributing corresponding authors 
 
Correspondence:  
Professor Anthony J. King, Consultant and Honorary Professor of Ophthalmology 
And 
Professor Harminder Singh Dua, Chair and Professor of Ophthalmology 
Nottingham University Hospitals and Academic section of Ophthalmology, Queens 
Medical Centre, Eye & ENT Building, B Floor, Derby Road, Nottingham NG7 2UH, 
United Kingdom 
Email:  Anthony.king@nottingham.ac.uk  and  Harminder.dua@nottingham.ac.uk  
 
Short running title: Ocular surface response to glaucoma medications  
 
Received 16 January 2020; accepted 18 June 2020 
 
This article is protected by copyright. All rights reserved.
 
Funding sources / Financial disclosure: International Glaucoma Association, Kent, 
UK; IGA research award. The funding organization had no role in the design or 
conduct of this research.  
 
Conflict of interest: HSD receives honoraria and travel expenses from Dompe, Thea, 
Santen, Allergan and Croma. Shares in GlaxoSmithKline and NuVision. AJK receives 








Background: Use of topical glaucoma medications has been reported to cause 
ocular surface (OS) discomfort and inflammation. This study explores the profile of 
inflammatory cytokines and OS symptoms induced in response to preserved and 
non-preserved drops. 
Methods: Prospective, randomized evaluation on thirty-six treatment-naïve patients 
over 24 months of three differently preserved glaucoma drop preparations: 
Preservative-free (PF), Polyquad (PQ), and Benzalkonium chloride (BAK). Study 
participants were evaluated at baseline and then at 1, 3, 6, 12 and 24 months whilst 
on medication.  At each visit, participants completed the Ocular Surface disease 
index (OSDI) questionnaire, had basal tear sampling and impression cytology (IC) of 
the conjunctival epithelium. Quantitative polymerase chain reaction was performed 
to measure the gene expression of inflammatory cytokines (Interleukin (IL)-6, IL-8, 
IL-10, IL-12A, IL-12B, IL-17A, IL-1β, and tumour necrosis factor (TNF)-α) in the IC 
samples. Corresponding protein expression of cytokines in tear samples was 
assessed by the Becton-Dickinson cytometric bead arrays.  
Results: Compared to PF and PQ groups, mRNA and protein expression of IL-6, IL-
8, and IL-1β increased in samples from the BAK group in a time-dependent fashion, 
whereas all other cytokines showed a non-significant increase. In the BAK group, 
there was a strong correlation between OSDI and the levels of IC/IL-1β (r=0.832, R 
squared=0.692 and p=0.040); IC/IL-10 (r=0.925, R squared=0.856 and p=0.008)  
and tear/IL-1β (r=0.899, R squared=0.808 and p=0.014). 
Conclusion: BAK-preserved topical drops stimulate a sterile inflammatory response 
on the OS within 3-months which is maintained thereafter. Whereas PF-drops and 
PQ-preserved drops showed no significant OS inflammation. 
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Primary open-angle glaucoma (POAG) is the leading cause of irreversible blindness 
worldwide.1-3  It affects approximately 73.6 million people globally with an estimated 
increase to 111.8 million in 2040 including 3.7% of UK and 2.6% of Oceania 
population aged between 48-92 years.1,3-5  Anti-glaucoma topical medications are 
widely used to control intra-ocular pressure (IOP) in POAG patients and are usually 
the first line treatment recommended.1,2,4  Evidence suggests that patients receiving 
long-term topical anti-glaucoma drops may develop ocular surface (OS) disease 
(conjunctival hyperaemia, dry-eye like syndrome and irritability) or experience 
aggravation of pre-existing OS disease.6  
 
Preservatives are used to prolong the shelf-life of glaucoma medications and some 
evidence suggested that their detergent properties increased the penetration of the 
active ingredients of the glaucoma drops.6,7  Benzalkonium chloride (BAK) is a 
quaternary ammonium compound that is the most widely used preservative in 
topical ophthalmic medication.6,7  It has been shown to have toxic effects on OS 
epithelia, inducing low-grade inflammation7-10 and may pose a risk for failure of 
glaucoma surgery.11,12  Polyquad (PQ) is polyquaternium-1 belonging to the family of 
polycationic polymers and is commonly used in contact-lens solution and topical 
ophthalmic medications.6  Experimental studies have demonstrated that PQ does not 
induce cytotoxic effects on the OS.13,14  However, the long-term effects of PQ-
preserved topical glaucoma medications on OS epithelia and patient experience 
remains unknown. 
 
The aim of this study was to evaluate the inflammatory effects of three different 
preserved glaucoma drop preparations on the OS of treatment naïve patients.  This 
involved the profiling of inflammatory cytokines on the ocular surface over a 24-
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month period and their correlation to changes in ocular surface discomfort as 





2.1 Study design 
The research was approved by the Nottingham Research Ethics Committee-1 (REC 
Ref: 13/EM/0225), the Research and Innovation unit of the Nottingham University 
Hospitals, National Health Service Trust (Ref: 12OY006) and the Medicine and 
Health Regulatory Authority (EudraCT number: 2013-000581-10), UK.  All research 
was conducted in accordance with the tenets of the Declaration of Helsinki.  Patients 
who met the inclusion and exclusion criteria were enrolled (Supplementary Table 1).  
Informed consent was obtained from each patient prior to enrolment. 
 
A single-center, pragmatic randomized controlled study design was adopted to 
explore the effect of preserved (bimatoprost 0.01%, travoprost 0.04%) and non-
preserved (latanoprost 0.005%, timolol 0.5%, dorzolamide 2%) topical anti-
glaucoma medications on the expression of cytokines at the OS.  Treatment-naïve 
glaucoma patients requiring topical hypotensive medication were enrolled and 
randomized into three groups, receiving either benzalkonium chloride (BAK), 
polyquad (PQ) or preservative free (PF) drops.  A computer-based randomization 
process provided by the Clinical Trials Unit of the University of Nottingham was used 
to determine study group allocation.  Study visits were scheduled at baseline (prior 
to commencement of medication), 1-, 3-, 6-, 12- and 24-months following therapy 
initiation.  There are no published longitudinal studies that demonstrated 
inflammatory effects of the preserved and PF drops on the patient OS. Therefore, as 
a guide to estimate the sample size, we utilised the outcomes of our previous 
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impression cytology studies15-17 that were unrelated to glaucoma drops.  It was 
estimated that n=8 samples/group will have 85% power at alpha=0.05 to detect 2-
fold difference (standard deviation = 0.5) in cytokine levels between the groups.  As 
a precautionary step and considering the possibility of attrition of samples and 
patient drop out during the study period, we collected samples from total 36 patient 
with 12 enrolled in each treatment group.  
 
At each visit, impression cytology and tear samples were taken, and patients 
completed the OS disease index (OSDI) questionnaire.  Where monotherapy was 
insufficient to control IOP, drops with the same class of preservative were added for 
further IOP lowering.  For PQ allocated patients only 2 PQ-preserved options exist 
(travoprost 0.004% monotherapy or travoprost 0.004%/timolol 0.5% combined 
therapy) if dual therapy was insufficient then the third medication added was PF.  
 
2.2 OSDI assessment 
The standard OSDI questionnaire consisting of 12 questions for assessment of 
symptoms, functional limitations and discomfort related to dry eye was used.18,19  
The questionnaire was administered by trained ophthalmic staff at the start of study 
and then at each follow-up visits. The baseline questionnaire was elicited prior to 
study group allocation.  In this questionnaire each question is graded on a scale of 0 
to 4, with 0 indicating ‘none of the time’ and 4 indicating ‘all the time’.  OSDI was 
calculated as: (sum of scores x 25) / (total number of questions answered).  An 
OSDI score between 0 and 100 was obtained.  Scores below 12 reflected normal OS 
health and above 33 indicated severe dry-eye condition.  
 
2.3 Sample collection  
Samples were collected using a microcapillary glass tube (5 µL, Drummond Scientific 
Co., PA) from canthal and inferior fornixes20 and stored at -80oC.  Conjunctival 
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epithelium was collected using impression cytology (IC) as previously reported.15  
Briefly, cellulose-ester discs of pore-size 0.45µm (Millipore Corporation, MA) and 
diameter of 13mm were cut into halves and applied to the upper and lower bulbar 
conjunctiva under topical anaesthesia (proxymetacaine hydrochloride 0.5%) for 10 
to 15 seconds.  The discs were gently peeled off and transferred into RNA lysis 
buffer (buffer RLT; Qiagen, UK).  
 
2.4 Total RNA isolation and cDNA synthesis 
Total RNA was isolated from the IC samples using RNeasy mini kit (Qiagen, UK) as 
per manufacturer’s instructions.  150ng of total RNA was then reverse transcribed 
into cDNA using QuantiTect RT kit (Qiagen, UK).  
 
2.5 Quantitative real-time polymerase chain reaction (qPCR)  
QPCR was performed to measure the relative fold-change of genes of interest using 
TaqMan probe assays (Supplementary Table 2; Applied Biosystems, UK).  Each 
reaction was prepared to 20µL final volume containing 5µL of diluted cDNA (1 in 5 
with nuclease-free (NF) water), 10µL of TaqMan gene expression master mix, 1µL of 
gene-of-interest, 1µL of endogenous gene (hypoxanthineguanine 
phosphoribosyltransferase-1 (HPRT1)) and 3µL of NF water.  Data was acquired on 
Mx3005p real-time PCR instrument (Stratagene/Agilent Technologies, UK) and 
analysed using delta-delta CT method as previously described.21  
 
2.6 Cytokine measurement  
Tear cytokines were measured using a BD-cytometric bead array (CBA) human 
inflammatory cytokines kit (BD Biosciences, UK) as previously reported.22  The tear 
samples were diluted 1 in 25 to a final volume of 50µL.  To diluted tear samples, 
50µL of each capture beads (phycoerythrin (PE) conjugated) and PE-detection 
reagents was added.  The mixture (150µL) was incubated in the dark for 3 hours 
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and then washed (x2 with wash buffer) via centrifugation. The resulting pellet was 
re-suspended in 300µL of wash buffer for beads analysis using BD-LSR II flow 
cytometer (BD Biosciences, UK).  The acquired data was further analysed using the 
FCAP array software version 3.0 (BD Biosciences, UK) and plotted using the Prism 
7.0 software (GraphPad software Inc. CA). 
 
2.7 Statistical analysis 
QPCR and CBA data were statistically analysed using the Prism 7.0 (GraphPad 
software Inc. CA). Two-way ANOVA was performed to evaluate the statistical 
differences between PF vs PQ, PF vs BAK, and PQ vs BAK, respectively. As our aim 
was to compare the effect of preservatives with preservative-free drops, we only 
reported the statistical data for the PF vs PQ and PF vs BAK groups. 
 
2.8 Masking 
Masking of patients and clinicians to treatment was not possible.  However, IC and 
tear samples were masked to group allocation and the analysis of biomarkers was 




3.1 Demographics and patient samples  
A total of 36 patients were recruited based on the study criteria (table 1) and 
randomized in to three groups: 12 in each of the preservative-free (PF), polyquad 
(PQ) group and benzalkonium chloride (BAK) group.  One participant from the BAK 
group withdrew after baseline sample collection.  
 
3.1.1 Impression cytology: 11 of the 35 IC samples could not be used due to low 
RNA quantity and/or RNA quality. Cytokine gene expression analysis using QPCR 
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was performed on the following IC samples (n=7 in PF; n=8 in PQ; and n=9 in 
BAK). 
 
3.1.2 Tear samples: It was not possible to analyse 8 of the 35 tear samples due to 
low collection volume (samples < 2 µL were not used). BD-CBA assay was only 
performed on complete patient samples (collection at all time points) in each group 
(n=7 in PF; n=8 in PQ; and n=9 in BAK).  
 
Demographic information of patients whose samples (n=24 in total had complete 
samples for all time-points) were analysed in this study are provided in table 1.  
Supplementary table 3 reports the intra-ocular pressure (IOP; mm Hg), visual acuity 
(VA) and visual field mean deviation (MD) of the three patients’ groups at baseline 
and 24-month.  There was a reduction in mean IOP at 24-month in all groups 
compared to baseline.   Mean group VA and mean MD in all groups remained 
unchanged at 24-month.  All patients were started on single drop treatment 
(latanoprost in PF, travoprost in PQ and bimatoprost in BAK) (Supplementary Table 
3).  In the PF group, all participants remained on a single drop throughout the 
study, one patient was started on an ocular lubricant (OL) at 12-month.  In the PQ 
group, four of the eight patients started dual drop therapy (travoprost + timolol) 
beginning at 3-month.  From 12-month onwards, two patients were on three drops 
with the third added drop (dorzolamide) being a PF formulation.  In addition, four of 
the patients on single drop in PQ group also received an OL. In the BAK group, two 
patients were moved to dual drop therapy (bimatoprost + timolol) starting 12-
month.  None of the patients in BAK group were commenced on an OL throughout 
the study. Refer the Consolidated Standards of Reporting Trials (CONSORT) flow-
diagram (supplementary figure 1) and the CONSORT checklist (supplementary table 
4) for further information.   
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3.2 Cytokine gene expression in conjunctival impression cytology samples  
All IC samples showed constitutive gene expression for IL-1β, TNF-α, IL-6, IL-8, IL-
10 and IL-12a but not IL-12b and IL-17a.  Three of the 6 cytokines namely IL-1β, 
IL-8 and IL-6 showed increased expression in the BAK group (figure 1).   
 
3.2.1 Interleukin 6 (IL-6): In the BAK group, IL-6 mRNA showed more than a 2-
fold increase in 7/9 samples at all time-points compared to baseline, but this did not 
reach statistical significance compared to PF and PQ groups.  On the other hand, the 
IL-6 mRNA levels in the PF and PQ groups was modestly increased at all time-points 
with no significant difference noted compared to baseline.   
 
3.2.2 Interleukin 8 (IL-8): In the BAK group, IL-8 mRNA (9/9 samples) was 
increased more than 4-fold starting at 1-month with significant elevated levels noted 
at 3-month (4.76-fold increase, p=0.0380) and 6-month (5.18-fold increase, 
p=0.0445).  Upon reaching 12-month, IL-8 was slightly reduced, but still remained 
elevated (9/9 samples) compared to PF and PQ groups. Unlike the BAK group, IL-8 
mRNA levels did not change significantly in PF and PQ groups at any time-point 
compared to baseline.   
 
3.2.3 Interleukin 1β  (IL-1β): In the BAK group, IL-1β  mRNA increased in a 
time-dependent manner from 3-month onwards with significantly increased level 
noted at 6-month (6.03-fold increase, p=0.0023; 9/9 samples), and remained at a 
similar high level until 24-month compared to baseline and all time-points in PF and 
PQ groups.  In the PQ group, there was a 2.92-fold increase in IL-1β  mRNA levels 
at 24 months. There was no change noted in the PF group at all time-points. 
 
3.2.4 Interleukin 10 (IL-10): IL-10 mRNA expression demonstrated a 1.5-fold 
increase in PF group starting 1-month and remained unchanged until 24-month (4/7 
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samples).   In the PQ group, IL-10 showed reduced expression until 12-month with 
slight elevation noted by 24-month (in 7/8 samples).  In the BAK group, IL-10 mRNA 
(in 5/9 samples) was modestly increased in a linear fashion starting at 3-months but 
failed to reach statistical significance compared to baseline and all time-points in PF 
and PQ groups.  
 
3.2.5 Tumour necrosis factor α (TNF-α) and Interleukin 12a (IL-12a): TNF-
α and IL-12a mRNA did not change significantly in either of the treatment groups.  
 
3.3 Quantification of cytokines in tear samples 
The baseline level of IL-6, IL-8, and IL-1β (83.34 ± 55.63 pg/mL, 1119.40 ± 674.68 
pg/mL and 2.06 ± 5.65 pg/mL, respectively) in all patients randomized into three 
groups were not significantly different (figure 2).  The number of patients who 
showed cytokines level above the detection limit of the BD-CBA assay kit has been 
detailed in supplementary table 5.   
 
3.3.1 Interleukin 6 (IL-6): In the BAK group, IL-6 showed elevated levels starting 
at 6-month time-point with significantly increased levels noted at 24-month (161.06 
± 73.91 pg/mL; p=0.0368; 9/9 samples) compared to PF group (41.69 ± 36.12 
pg/mL; 5/7 samples).  There was also a mild non-significant elevation in IL-6 levels 
in the PQ group beginning at 6 months, which remained at a similar level until 24-
month time-point.   
 
3.3.2 Interleukin 8 (IL-8): In the BAK group, IL-8 showed increased levels 
beginning at 3-month (2770.51 ± 1016.05 pg/mL; p=0.0244; 9/9 samples), which 
remained elevated until 24 months (1827.54 ± 1038.21 pg/mL; p=0.0388; 9/9 
samples) compared to PF group (328.42 ± 186.45 pg/mL; 6/8 samples). In the PQ 
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group, IL-8 was modestly increased with no statistical significance noted at all time-
points compared to PF group.  
 
3.3.3 Interleukin 1β  (IL-1β): In the BAK group, IL-1β showed significant 
elevated levels starting at 3-month (11.79 ± 8.18 pg/mL; p=0.0243; 6/9 samples) 
with elevated levels noted at 24-month (17.09 ± 9.74 pg/mL; p=0.0187; 6/9 
samples) compared to PF group (1.58 ± 3.54 pg/mL; 2/7 samples).  A mild elevation 
of IL-1β levels was also noted at all time-points for the PQ group.  
 
3.3.4 Other cytokines: IL-10, IL-12p70 (a heterodimer encoded by IL-12a gene), 
and TNF-α was detected at inconsistent low-levels in up to 2 of 8 patient samples 
(refer Supplementary table 5 for details regarding number of patients that showed 
cytokines above the detection limit of BD-CBA assay kit).  
 
3.4 Ocular Surface Disease Index (OSDI) evaluation 
The mean OSDI score was evaluated for the patients whose samples were used for 
cytokine estimation.  All patients randomized to the PF, PQ, and BAK groups showed 
similar OSDI scores at the baseline (mean OSDI = 5.22) and there was no 
significant difference between the groups (figure 3).  
 
For the PF group, the mean OSDI score was less than 12 for 6/7 patients at all time-
points.  
For the PQ group, the mean OSDI score was more than 12 starting at 6-month in 
4/8 patients, with 1 of 8 patients was scored more than 20 at 24-month.   
For the BAK group, the mean OSDI score was more than 20 at 12-months (5/9 
patients; p<0.0001), with 3 of 9 patients was scored more than 30 at 24-month 
(p<0.0001) compared to PF group.   
 
This article is protected by copyright. All rights reserved.
 
As shown in table 2, the linear correlation between OSDI and cytokines [OSDI vs IC-
cytokines and OSDI vs tear-cytokines] was measured using the Pearson correlation 
test method.  We have noted a significant correlation between OSDI and IC/IL-1β 
(r=0.832, R squared=0.692 and p=0.040), OSDI and IC/IL-10 (r=0.925, R 
squared=0.856 and p=0.008) and OSDI and tear/IL-1β (r=0.899, R squared=0.808 
and p=0.014).  However, the correlation between OSDI and tear level for TNF-α, IL-
10 and IL-12p70 was not determined since these were only detected in insignificant 




Topical drops are the primary treatment for patients with glaucoma.  Evidence 
suggests that the presence of BAK preservative in drops may lead to ocular 
irritation, tear-film instability, chronic inflammation, subconjunctival fibrosis, and 
increase the risk for failure of glaucoma filtration surgery.8,9,23  BAK-preserved drops 
have been implicated in the development of subclinical ocular surface inflammation 
through increased levels of inflammatory mediators.10,24,25  Unlike previous reports, 
which are often cross sectional, in this study we have undertaken a three-way 
evaluation of different preservative effects on treatment-naïve patients and profiled 
the temporal effect of these on cytokines in IC and tear samples.  
 
Cytokines and chemokines are known to be secreted from a variety of cell types in 
response to infectious or inflammatory stimuli.  These proteins may then trigger 
activation of intracellular signalling, enhancing cell proliferation/differentiation or 
lead to programmed cell death.26  IL-1β and TNF-α are known to induce other 
cytokines/chemokines and profibrotic growth factors leading to sterile inflammation27 
and tissue fibrosis.28  IL-6 and IL-8 (CXCL8) are proinflammatory cytokine with the 
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ability to amplify autoimmune responses via the activation of infiltrating neutrophils 
and T-cells.26  
 
Impression cytology provides an alternative to biopsy or scraping to obtain 
conjunctival cells for  cell-surface markers analysis using flow cytometry25 and gene 
expression studies of host defense genes.29  Normal conjunctival epithelium 
collected using the IC technique has been shown to express constitutive mRNA 
levels of IL-1, IL-6, IL-8, TNF-α.30  In response to inflammatory stimuli, these have 
been  produced both at mRNA and protein level.30  Elevated expression of IL-1β, IL-
6 and IL-8 have been reported in the conjunctival IC samples of patients with 
Sjogren’s syndrome keratoconjunctivitis sicca31 and dry-eye condition.32  
Conjunctival IC samples from patients on BAK-preserved anti-glaucoma drops show 
elevated expression of human leucocyte antigen (HLA)-DR, IgE, IL-8 and two 
chemokine receptors (CCR4 and CCR5)10,24,25 and increased levels of T helper (Th)-1 
inflammatory cytokines have been demonstrated in tear samples of patients 
receiving preserved anti-glaucoma medications for more than 6-months duration.33  
BAK also induces cytokine production from trabecular meshwork cells in laboratory 
studies.34  
 
Our study demonstrates that mRNA for cytokines are constitutively expressed in 
conjunctival epithelium samples at baseline.  An explanation for increased levels of 
IL-6, IL-8 and IL-1β in IC in the tear samples of patients randomised to the BAK 
group during the study could be that these cytokines are sensitive to any 
inflammatory stimuli and their homeostatic balance is key for maintenance of 
immune-privilege status of OS.35  Although we have demonstrated the matching 
trend of both mRNA and protein expression of cytokines in samples from BAK group, 
it is likely that conjunctival epithelium may not be the only source for tear cytokines.  
Other possible sites for cytokine secretion in response to BAK are corneal 
This article is protected by copyright. All rights reserved.
 
epithelium,36 tenon’s fibroblast37 and limbal-resident immune cells.38  A previous 
study has demonstrated that the levels of tear IL-1β and TNF-α increased in patients 
on multiple BAK-containing drops compared to those on single drop therapy i.e., 
concentrating effect of BAK on ocular inflammation.33  Here, all our patients 
randomized to the BAK group were on a single drop and have shown time-
dependent increase in IL-6, IL-8 and IL-1β levels.  
 
The advantages of PF over preserved medication for glaucoma treatment has been 
widely reported.39-41  Similarly, as evident from OSDI scoring, our patient group on 
PF and PQ containing drops have not complained of OS discomfort which can be 
correlated with reduced levels of inflammatory cytokines.  On the other hand, those 
randomized to BAK-preserved drops had a high OSDI score, which strongly 
correlated to elevated levels of IL-1β. Recent phase III-b clinical trials have 
demonstrated that switching patients from BAK-preserved latanoprost to PF-
tafluprost have improved OS tolerability and patient compliance within 12-weeks.41  
 
PQ has been previously shown to be safe and did not induce cytotoxic/inflammatory 
effects on OS epithelium in in-vitro or in-vivo studies.13,14  Samples from our patient 
cohort using PQ-preserved drops have shown moderately high levels of IL-1β and 
IL-6 from 12-month onwards.  This is also mimicked in the trends noted in the OSDI 
results. Our results suggest that chronic, long-term use of PQ preserved drops could 
induce delayed subclinical OS inflammation.  
 
One criticism could be that some of the effects may be related to other non-
preservative components of the drops.  Previous in-vitro studies have successfully 
compared the inflammatory and cytotoxic effects of widely used prostaglandin 
analogues: latanoprost, travoprost, and bimatoprost. 42,43 Notably, none of these 
three analogues was shown to induce inflammatory markers in cultured conjunctival 
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epithelial cells. Similarly, our study has also demonstrated that the addition of PF-
timolol between 12- and 24-month duration as a second active drug has no 
significant effect on the cytokine levels; even in PF-latanoprost group.  This is 
consistent with previous studies that demonstrated non-toxic effects of PF-timolol 
and PF-latanoprost on OS epithelium compared to BAK-preserved timolol and 
latanoprost drops, respectively.30,39  Clinical studies have shown that patients on 
bimatoprost frequently develop ocular hyperemia.44-47 This effect of bimatoprost 
0.03% on OS has been confirmed to be due to vasodilation mediated via over-
production of nitric oxide synthase, but not due to the induction of inflammatory 
cytokines.44,48    
 
Our observation that BAK is responsible for the increased expression of cytokines is 
consistent with numerous studies that evaluated the inflammatory markers in tears 
of patients treated with preservative-containing and PF drops.8-10,25,33,38 These 
published observations though cannot exclude the possibility of an unknown 
inflammatory effect from bimatoprost. The magnitude of effect if any exists in our 
BAK patient group is likely to be negligible and it does not detract from the 
observations or conclusions of this report. However, a future study is warranted to 
validate and compare the OS responses in patients on PF-bimatoprost 0.01% versus 
BAK-bimatoprost 0.01%, PF-latanoprost 0.005% versus BAK-latanoprost 0.005%, 
and PF-travoprost 0.04% versus BAK-travoprost 0.04%.   
 
The strengths of this study are following: 
1. A first of its kind, prospective evaluation of the changes in ocular surface 
markers of inflammation in treatment-naïve patients that were randomised to 
three preserved options available for glaucoma drops.   
2. Baseline sampling of treatment-naïve patients for comparative analysis of 
cytokines over a period of 24-months have successfully reduced the effect of 
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confounding variables. BL samples showed no significant differences in the 
baseline cytokine levels across the three groups.   
3. Statistical correlation between the ocular surface inflammatory changes and 
clinical symptoms as measured by the OSDI tool was successfully 
demonstrated. 
 
The weakness is that we have recruited and analysed relatively small numbers (due 
to poor sample quality and/or quantity). Although even with this small sample size, 
we have demonstrated a clear effect on inflammatory markers in IC and tear 
samples. The use of different prostaglandin analogues in each of the preservative 
groups introduces slight uncertainty into the possibility that some of the 
inflammatory effects in the BAK group may be related to active ingredient, 
bimatoprost. 
 
In conclusion, our results have demonstrated that patients on BAK preparation 
showed increased OS inflammation compared to those on PF and PQ-preserved 
preparations. The inflammatory effect of BAK was detectable starting 3 months and 
sustained for the duration of the 24-month follow-up. The strong correlation seen 
between OSDI scores and increased levels of cytokines in BAK group supports the 
conclusion that BAK induces ocular discomfort in patients.7-10  There is a suggestion 
that PQ is also capable of producing delayed OS inflammatory response, which may 
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 Preservative - free Polyquad Benzalkonium chloride 
Gender 
(male/ female) 3/4 2/6 6/3 
Age in years 
mean (SD) 67.9 (5.0) 70.3 (12.7) 63.9 (10.9) 
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Table 2: Pearson correlation of OSDI with cytokines level in conjunctival impression 












































































































N.D. - Not determined; CI – Confidence interval 






Figure 1: Gene expression analysis of cytokines in conjunctival impression cytology 
(IC) samples. Based on 24 patients with complete data collection. Relative fold change 
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(RFC; Y-axis) of IL-6, IL-8, IL-1β, TNF-α, IL-10 and IL-12a in IC samples that are 
collected at different durations (in months; X-axis) from patients on anti-glaucoma 
medications that are preservative-free (PF) and preserved with polyquad (PQ) and 
benzalkonium chloride (BAK), respectively. RFC is represented as mean ± standard 
deviation. Two-way ANOVA was performed to assess the statistical significance 
between PF vs PQ and PF vs BAK groups with alpha level set at p=0.05. 
  


























































































































































































































































































































































































































Figure 3: Ocular surface disease index (OSDI). Box plot represents the OSDI score 
for n=24 patients with complete data collection. OSDI was calculated based on 
questionnaire completed by patients, randomised to preservative-free (PF) and 
preserved (polyquad (PQ) and benzalkonium chloride (BAK)) anti-glaucoma 
medications, at baseline (BL) and at each subsequent visit (1, 3, 6, 12 and 24 
months; X-axis). Data is represented as mean (solid line in the box) with minimum 
and maximum OSDI values indicated as vertical bars. Two-way ANOVA was 
performed to assess the statistical significance between PF vs PQ and PF vs BAK 
groups with alpha level set at p=0.05. * denotes p<0.05 and *** denotes p<0.001.  
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